Edition:
United Kingdom

Natus Medical Inc (BABY.OQ)

BABY.OQ on NASDAQ Stock Exchange Global Select Market

26.15USD
3:34pm BST
Change (% chg)

$-0.20 (-0.76%)
Prev Close
$26.35
Open
$26.14
Day's High
$26.22
Day's Low
$25.94
Volume
5,249
Avg. Vol
118,120
52-wk High
$37.95
52-wk Low
$23.58

Latest Key Developments (Source: Significant Developments)

Natus Medical Q1 GAAP Loss Per Share $0.74
Thursday, 25 Apr 2019 

April 25 (Reuters) - Natus Medical Inc ::ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.SEES Q2 2019 NON-GAAP EARNINGS PER SHARE $0.25 TO $0.32.Q1 NON-GAAP EARNINGS PER SHARE $0.09.Q1 GAAP LOSS PER SHARE $0.74.SEES Q2 2019 REVENUE $121 MILLION TO $125 MILLION.Q1 REVENUE $114.8 MILLION VERSUS $128.6 MILLION.INC - SEES 2019 REVENUE $489.0 MILLION AND $505.0 MILLION.INC - SEES 2019 NON-GAAP EARNINGS EXPECTED PER SHARE $1.17 AND $1.44.INC - ANNOUNCED "ONE NATUS" REORGANIZATION, STREAMLINING OPERATIONS WITH EXPECTED BENEFITS OF OVER $4.0 MILLION IN 2019.  Full Article

Natus Says Will Consolidate Its Three Business Units, Neuro, Newborn Care And Otometrics Into "One Natus"
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Natus Medical Inc ::NATUS ANNOUNCES ORGANIZATIONAL ENHANCEMENTS, KEY LEADERSHIP APPOINTMENTS.NATUS MEDICAL INC - WILL CONSOLIDATE ITS THREE BUSINESS UNITS, NEURO, NEWBORN CARE AND OTOMETRICS INTO "ONE NATUS".NATUS MEDICAL INC - COMPANY WILL IMMEDIATELY TRANSITION TO NEW STRUCTURE WITH FURTHER IMPLEMENTATION STAGES CONTINUING THROUGHOUT 2019.NATUS MEDICAL INC - EXPECTS TO EXIT TWO NON-CORE BUSINESSES.NATUS MEDICAL INC - EXPECTS TO EXIT GLOBAL NEURODIAGNOSTICS & NEUROCOM BALANCE PRODUCT LINE.NATUS MEDICAL INC - GND BUSINESS ACCOUNTED FOR APPROXIMATELY $12 MILLION IN REVENUE DURING 2018..NATUS MEDICAL INC - REVENUE FROM NEUROCOM PRODUCT LINE WAS APPROXIMATELY $7 MILLION DURING 2018..  Full Article

Natus Announces $30 Million Share Repurchase Program
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Natus Medical Inc ::NATUS ANNOUNCES $30 MILLION SHARE REPURCHASE PROGRAM.NATUS MEDICAL - TO USE CASH ON HAND, CASH GENERATED FROM OPERATIONS, EXISTING CREDIT FACILITIES OR OTHER FINANCING TO FUND SHARE REPURCHASE PROGRAM.  Full Article

Natus Medical Announces 2018 Annual And First Quarter Financial Guidance
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Natus Medical ::REVENUE IN Q4 WAS LOWER THAN EXPECTED DUE TO WEAKNESS IN OUR U.S. NEURODIAGNOSTIC BUSINESS.‍FULL YEAR AND Q1 2018 NON-GAAP GUIDANCE DOES NOT INCLUDE EXPENSES FOR U.S. MEDICAL DEVICE TAX​.DUE IN PART TO DISRUPTION FROM INTEGRATION OF COMPUTER SYSTEMS, Q4 REVENUE ALSO LOWER THAN EXPECTED AT OTOMETRICS.‍IF NOT REPEALED OR SUSPENDED, MEDICAL DEVICE TAX WILL HAVE AN ANNUAL AFTER TAX COST OF APPROXIMATELY $3.0 MILLION​.INCREASING INVESTMENTS IN KEY PRODUCT AREAS IN 2018.ANNOUNCES 2018 ANNUAL AND FIRST QUARTER FINANCIAL GUIDANCE.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $1.60 TO $1.65.SEES Q1 2018 REVENUE $125 MILLION TO $127 MILLION.SEES FY 2017 REVENUE $500.5 MILLION TO $501.5 MILLION.SEES FY 2018 REVENUE $535 MILLION TO $540 MILLION.SEES Q1 2018 NON-GAAP EARNINGS PER SHARE $0.23 TO $0.24.SEES Q4 2017 REVENUE ABOUT $131 MILLION TO $132 MILLION.EXPECT OTOSCAN REVENUES TO RAMP IN SECOND HALF OF 2018.  Full Article

Natus Medical Inc reports ‍Q3 loss per share of $0.26​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Natus Medical Inc :Natus Medical Inc - ‍Q3 2017 loss per share $0.26​.Sees FY 2017 non-GAAP earnings per share $1.72 to $1.76.Natus Medical Inc qtrly ‍adj earnings per share $0.40​.Sees Q4 2017 non-GAAP earnings per share $0.68 to $0.72.Natus Medical Inc - ‍for Q3, company reported revenue of $122.6 million, an increase of 34.9% compared to $90.9 million reported for Q3 2016​.Sees FY 2017 revenue $514.5 million to $516.5 million.Sees Q4 2017 revenue $145 million to $147 million.Q3 earnings per share view $0.38, revenue view $122.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.70, revenue view $508.7 million -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.69, revenue view $136.5 million -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences to sell neurosurgery assets to Natus Medical
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Integra Lifesciences Holdings Corp :Integra Lifesciences announces definitive agreement to sell certain neurosurgery assets to Natus Medical Incorporated.Integra Lifesciences announces definitive agreement to sell certain neurosurgery assets to Natus Medical Incorporated.Integra Lifesciences - preliminary estimate for Q4 2017 revenue contribution of about $60 million-$65 million from acquisition of Codman Neurosurgery, net of divestitures​.Integra Lifesciences- continues to expect Codman Neurosurgery's accretive contribution to adjusted earnings per share to be at least $0.22 in 2018.Integra Lifesciences - ‍for FY 2018, Integra expects Codman Neurosurgery to contribute between $290 million and $300 million in revenue, net of divestitures​.Integra Lifesciences - ‍continues to Expect Codman Neurosurgery's accretive contribution to adjusted earnings per share to be at least $0.22 in 2018​.Integra Lifesciences Holdings - ‍divestiture contingent on consummation of Integra's proposed acquisition of Codman Neurosurgery from Johnson & Johnson​.Integra Lifesciences Holdings Corp - ‍for full year 2017, integra expects minimal contribution from Codman Neurosurgery to adjusted earnings per share​.  Full Article

Natus to acquire neurosurgery assets from Integra Lifesciences
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Natus Medical Inc :Natus to acquire neurosurgery assets from Integra Lifesciences, enters neurosurgery market.Natus Medical Inc - deal for ‍all cash transaction for $47.5 million​.Natus Medical Inc - deal for ‍$47.5 million​.Natus Medical Inc - ‍natus will use cash on hand and available from its credit facility to fund acquisition​.Natus Medical Inc - ‍as part of deal, Natus will acquire global Camino Icp monitoring product line, including its San Diego manufacturing facility​.Natus Medical - ‍sale also includes U.S. rights relating to Integra's fixed pressure shunts, U.S. rights to Codman's duraform dural graft implant​.Natus Medical Inc - ‍expect deal to be immediately accretive to earnings with gross and operating margins similar to our consolidated margins​.  Full Article

Natus Medical Q2 GAAP loss per share $0.15
Wednesday, 26 Jul 2017 

July 26 (Reuters) - Natus Medical Inc :Natus Medical announces second quarter 2017 financial results.Q2 non-GAAP earnings per share $0.34.Q2 GAAP loss per share $0.15.Q2 revenue $122.2 million versus I/B/E/S view $122 million.Q2 earnings per share view $0.33 -- Thomson Reuters I/B/E/S.Sees FY 2017 non-GAAP earnings per share $1.70 to $1.75.Sees FY 2017 revenue $505 million to $510 million.FY2017 earnings per share view $1.70, revenue view $504.6 million -- Thomson Reuters I/B/E/S.Sees Q3 2017 non-GAAP earnings per share $0.37 to $0.38.Sees Q3 2017 revenue $121 million to $123 million.Q3 earnings per share view $0.41, revenue view $122.2 million -- Thomson Reuters I/B/E/S.Natus Medical Inc - direct and transition costs of Otometrics acquisition estimated to be approximately $3 million to $4 million for full year 2017.  Full Article

Natus Medical CEO James Hawkins purchases 4000 shares of co's common stock - SEC Filing
Thursday, 15 Jun 2017 

June 15 (Reuters) - Natus Medical Inc :Natus medical inc ceo james hawkins reports purchase of 4000 shares of co's common stock on june 15 at $33.98 per share - sec filing.  Full Article